Monday, September 21, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

GLP-1oral semaglutidedpp-4 inhibitorshfpefcognition

Journal comment questions oral semaglutide cognition findings in HFpEF

Correspondence in Internal and Emergency Medicine responds to a comparison of oral semaglutide with DPP-4 inhibitors in older patients with obesity and heart failure.

MH
By Maren Holt · Senior Reporter, GLP-1
Sep 18 20:00 ETSource: Internal and emergency medicine

The wire

  1. 01A letter published 19 September comments on reported reductions in cognitive impairment risk with oral semaglutide versus DPP-4 inhibitors in elderly patients with HFpEF and obesity.
  2. 02Clinicians weighing incretin therapy in older cardiometabolic patients should note that the underlying comparison is being contested in the literature.
  3. 03The item is correspondence, not new data; the original study's authors may respond and the question remains unresolved.

From the source

Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity: comment

Internal and emergency medicine · 2026 Sep 19 · Odic P, Nardi O, Foucault-Fruchard L et al.

Read at pubmed.ncbi.nlm.nih.gov
Source URL https://pubmed.ncbi.nlm.nih.gov/42762372/